Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus SODIUM FLUORIDE F 18.
CERETEC vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical